Compare Bank of America Corp (BAC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Bank of America Corp trades at $64.03 (market cap $446.56B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Bank of America Corp is far larger — about 5.4× Regeneron Pharmaceuticals Inc's market cap, and Bank of America Corp pays the higher dividend (2%). Which is the better fit depends on your goals.
| BAC | REGN | |
|---|---|---|
Market Cap | $446.56B | $83.19B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $812.27 |
52-Week Low | $46.72 | $555.51 |
Dividend Yield | 2% | 0.47% |
Enterprise Value | — | $77.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
